GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

Share on Pinterest Research in mice shows how aspirin may boost the immune response against cancer, keeping secondary tumors at bay. Image credit: AsiaVision/Getty Images. Around half of all ...

New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...

Apr. 2, 2025 — Scientists are working to create a new light-activated 'smart' bomb to treat aggressive breast cancer. The new light-sensitive chemicals called cyanine-carborane salts are used in ...

Lucy Notarantonio is Newsweek's Senior Lifestyle and Trends Reporter, based in Birmingham, UK. Her focus is trending stories and human interest features ranging from health, pets and travel.

Pay attention to your instincts, Cancer. They’re bound to be on point today while the moon hovers in Gemini and your intuitive, empathic twelfth house. You could get the feeling that someone ...

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care. After being diagnosed with colon cancer, I learned ...

USCAP 2025 Risk-Reduction Surgery Benefit in Non-BRCA Ovarian Cancer? A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...